Literature DB >> 23224992

Commentary on "Transdermal DMPS".

Charles McKay.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23224992      PMCID： PMC3576507          DOI： 10.1007/s13181-012-0277-4

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN： 1556-9039


× No keyword cloud information.
  7 in total

Review 1.  Biopharmaceutics and pharmacokinetics in drug research.

Authors:  R Panchagnula; N S Thomas
Journal:  Int J Pharm       Date:  2000-05-25       Impact factor: 5.875

2.  American College of Medical Toxicology position statement on post-chelator challenge urinary metal testing.

Authors: 
Journal:  J Med Toxicol       Date:  2010-03

3.  ACMT position statement: the Iom report on thimerosal and autism.

Authors:  Tom L Kurt
Journal:  J Med Toxicol       Date:  2006-12

4.  Plasma and urine dimercaptopropanesulfonate concentrations after dermal application of transdermal DMPS (TD-DMPS).

Authors:  Jennifer P Cohen; Anne-Michelle Ruha; Steven C Curry; Kallol Biswas; Benjamin Westenberger; Wei Ye; Kathleen L Caldwell; Frank Lovecchio; Keith Burkhart; Nasr Samia
Journal:  J Med Toxicol       Date:  2013-03

5.  A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders.

Authors:  David A Geier; Mark R Geier
Journal:  J Toxicol Environ Health A       Date:  2007-05-15

6.  Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides.

Authors:  R M Maiorino; Z F Xu; H V Aposhian
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

7.  Mobilization of mercury and arsenic in humans by sodium 2,3-dimercapto-1-propane sulfonate (DMPS).

Authors:  H V Aposhian
Journal:  Environ Health Perspect       Date:  1998-08       Impact factor: 9.031
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.